On November 13, 2026, a clinical trial update was recorded for setmelanotide in patients with Prader-Willi syndrome. The study, titled "A Study of Setmelanotide in Patients With Prader-Willi Syndrome," is registered under identifier NCT06772597. It is listed as a Phase 2 trial. Its current status is active but not recruiting, meaning the study is ongoing but is not currently enrolling new participants. No results have been reported as part of this update. This status reflects only the trial's recruitment stage and does not indicate any outcome, efficacy, or safety finding for setmelanotide in this population. Setmelanotide is an approved compound, and this trial represents an additional investigation into its use in a specific patient group. Further updates to this trial's status, including any eventual results, would be reported separately as they become available on the public registry. Readers interested in background on setmelanotide, including its approved uses and general profile, can consult the compound overview for additional context.
Setmelanotide Phase 2 Trial in Prader-Willi Syndrome Now Active
See the full setmelanotide overview
Source: https://clinicaltrials.gov/study/NCT06772597